Glenmark under fire for over pricing, 'misguided' claims of Covid-19 drug

NCP legislator Amol Kolhe's letter to Health Minister Harsh Vardhan triggers the DCGI to seek details from the Mumbai-based drugmaker

Glenmark, which markets favipiravir under brand Fabiflu for treatment of mild-to-moderate Covid-19 patients, has come under the scanner of ‘the country’s drug regulator over pricing of the drug and claims of its therapeutic efficacy.

The Drug Controller General of India (DCGI) has sent a letter to the Mumbai-based drugmaker seeking clarifications on pricing as well as claims of therapeutic efficacy.

The move was triggered by a letter Nationalist Congress Party legislator Amol Kolhe wrote addressed to the health minister.

The DCGI had given emergency use authorisation to favipiravir in the third week of June. It was an expedited approval following